LignaMed Overview
- Founded
-
2013
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$916K
- Investors
-
4
LignaMed General Information
Description
Developer of molecule therapy intended to offer breakthrough treatments for severe asthma, organ transplant viability, and fibrosis. The company develops therapeutics from flaxseed derivatives obtained through proprietary synthesis processes and also offers an oral treatment for Th2-low asthma, to salvage donor lung organs that are currently not suitable for a lung transplant, enabling patients to improve donor lung storage conditions and extend the donor lung preservation period, as an oral treatment for Pulmonary Fibrosis control and in some cases reverse the progression of the disease.
Contact Information
Website
www.lignamed.com
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
- 3675 Market Street
- Suite 200
- Philadelphia, PA 19104
- United States
LignaMed Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Grant | 01-Sep-2018 | $916K | Completed | |||
| 6. Grant | 18-Jul-2017 | 00000 | Completed | |||
| 5. Grant | 01-Jan-2020 | 00.000 | Completed | Startup | ||
| 4. Grant | 01-Jan-2019 | 00.000 | Completed | Startup | ||
| 3. Grant | 01-Jan-2018 | 00000 | Completed | Startup | ||
| 2. Grant | 01-Jan-2017 | $403K | Completed | Startup | ||
| 1. Accelerator/Incubator | 10-Mar-2015 | Completed | Startup |
LignaMed Patents
LignaMed Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2018283958-B2 | Process for the preparation of (s,s)-secoisolariciresinol diglucoside and (r,r)-secoisolariciresinol diglucoside | Inactive | 12-Jun-2017 | 000000000 | |
| EP-3638220-A4 | Process for the preparation of (s,s | Pending | 12-Jun-2017 | 000000000 | |
| JP-2020523394-A | Method for producing (s,s)-secoisolariciresinol diglucoside and (r,r)-secoisolariciresinol diglucoside | Pending | 12-Jun-2017 | 000000000 | |
| US-20200181187-A1 | Process for the preparation of (s,s)-secoisolariciresinol diglucoside and (r,r)-secoisolariciresinol diglucoside | Inactive | 12-Jun-2017 | 000000000 | |
| CA-3065386-A1 | Process for the preparation of (s,s)-secoisolariciresinol diglucoside and (r,r)-secoisolariciresinol diglucoside | Pending | 12-Jun-2017 | C07H1/00 |
LignaMed Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| David Leach | Chief Executive Officer | ||
| Thais Sielecki Ph.D | Chief Scientific Officer | ||
| Melpo Christofidou-Solomidou Ph.D | Founder & Chairman of Scientific Advisory Board |
LignaMed Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| James Harris | Self | Chairman | 000 0000 |
| Melpo Christofidou-Solomidou Ph.D | LignaMed | Founder & Chairman of Scientific Advisory Board | 000 0000 |
| Michael Dishowitz Ph.D | Self | Board Member | 000 0000 |
| Philip Sass Ph.D | Self | Board Observer & Advisor | 000 0000 |
LignaMed Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
LignaMed Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| National Aeronautics and Space Administration | Government | 000 0000 | 000000 0 | ||
| National Institutes of Health | Government | 000 0000 | 000000 0 | ||
| U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 | ||
| UPstart (Philadelphia) | Accelerator/Incubator | 000 0000 | 000000 0 |